Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine

Published:2017-12-09 Issue:1 Volume:109 Page:215-224
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Ikeda Masafumi¹^ORCID,Ioka Tatsuya²,Fukutomi Akira³,Morizane Chigusa⁴,Kasuga Akiyoshi⁵,Takahashi Hideaki¹,Todaka Akiko³,Okusaka Takuji⁴,Creasy Caretha L.⁶,Gorman Shelby⁶,Felitsky Daniel J.⁷,Kobayashi Mikiro⁸,Zhang Fanghong⁸,Furuse Junji⁵^ORCID

Affiliation:

1. Department of Hepatobiliary and Pancreatic Oncology; National Cancer Center Hospital East; Kashiwa Japan

2. Osaka International Cancer Institute; Osaka Japan

3. Shizuoka Cancer Center; Shizuoka Japan

4. National Cancer Center Hospital; Tokyo Japan

5. Department of Medical Oncology; Kyorin University; Tokyo Japan

6. GlaxoSmithKline; Philadelphia PA USA

7. Jounce Therapeutics; Cambridge MA USA

8. Novartis Pharma; Tokyo Japan

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13438/fullpdf

Reference37 articles.

1. Systemic therapy for biliary tract cancers;Hezel;Oncologist,2008

2. National Cancer Center Cancer statistics in Japan 2009 http://www.fpcr.or.jp/publication/statistics.html

3. Biliary tract cancers: SEOM clinical guidelines;Benavides;Clin Transl Oncol,2015

4. Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations;Marcano-Bonilla;Chin Clin Oncol,2016

5. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature;Supportive Care in Cancer;2024-08-23

2. Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis;Future Oncology;2024-04

3. Predicting the molecular mechanism-driven progression of breast cancer through comprehensive network pharmacology and molecular docking approach;Scientific Reports;2023-08-22

4. Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy;Annals of Hepato-Biliary-Pancreatic Surgery;2023-02-24

5. Establishment of two oxaliplatin-resistant gallbladder cancer cell lines and comprehensive analysis of dysregulated genes;Open Medicine;2023-01-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3